Protalix BioTherapeutics Inc (PLX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protalix BioTherapeutics Inc (PLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10121
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease; cystic fibrosis and gaucher disease. Protalix develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology: ProCellEx System. Protalix is headquartered in Carmiel, Israel

Protalix BioTherapeutics Inc (PLX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Protalix Enters Into Technology Transfer Agreement With Oswaldo Cruz Foundation For Uplyso 10
Licensing Agreements 12
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 12
Equity Offering 14
Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 14
Protalix BioTherapeutics Completes Public Offering Of Common Stock For US$27 Million 15
Debt Offering 17
Protalix BioTherapeutics Raises USD22.5 Million in Private Placement of Notes 17
Protalix BioTherapeutics Completes Private Placement Of Notes Due 2018 For US$69 Million 18
Acquisition 19
Protalix BioTherapeutics Mulls Offering Itself For Sale 19
Protalix BioTherapeutics Inc – Key Competitors 20
Protalix BioTherapeutics Inc – Key Employees 21
Protalix BioTherapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2018: Protalix BioTherapeutics reports 2018 third quarter results and provides corporate update 23
Aug 09, 2018: Protalix BioTherapeutics reports 2018 second quarter results and provides corporate update 24
May 09, 2018: Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update 25
Mar 06, 2018: Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update 26
Nov 08, 2017: Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update 27
Aug 09, 2017: Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update 28
May 10, 2017: Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update 30
Mar 16, 2017: Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update 31
Jan 09, 2017: Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017 32
Corporate Communications 33
Aug 13, 2018: Protalix Biotherapeutics names David Granot as board director 33
Clinical Trials 34
Jan 03, 2017: Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase) for the Treatment of Cystic Fibrosis 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalix BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Protalix Enters Into Technology Transfer Agreement With Oswaldo Cruz Foundation For Uplyso 10
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 12
Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 14
Protalix BioTherapeutics Completes Public Offering Of Common Stock For US$27 Million 15
Protalix BioTherapeutics Raises USD22.5 Million in Private Placement of Notes 17
Protalix BioTherapeutics Completes Private Placement Of Notes Due 2018 For US$69 Million 18
Protalix BioTherapeutics Mulls Offering Itself For Sale 19
Protalix BioTherapeutics Inc, Key Competitors 20
Protalix BioTherapeutics Inc, Key Employees 21
Protalix BioTherapeutics Inc, Subsidiaries 22

List of Figures
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Protalix BioTherapeutics Inc (PLX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Admedes GmbH:企業の戦略的SWOT分析
    Admedes GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hobby Lobby Stores Inc:戦略・SWOT・企業財務分析
    Hobby Lobby Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Hobby Lobby Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Salem Media Group, Inc.:企業の戦略・SWOT・財務情報
    Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bulgarian Telecommunications Company (VIVACOM):企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Chori Co Ltd (8014):企業の財務・戦略的SWOT分析
    Chori Co Ltd (8014) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Storopack Hans Reichenecker GmbH:企業の戦略的SWOT分析
    Storopack Hans Reichenecker GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Lamellar Biomedical Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Lamellar Biomedical Ltd (Lamellar Biomedical) is a biotechnology company that develops medical products using based on mimetics of extra-alveolar lamellar bodies. The company develops products using its proprietary Lamellasome technology that are mimetics of native extra-alveolar lamellar th …
  • Flour Mills of Nigeria Plc (FLOURMILL):企業の財務・戦略的SWOT分析
    Flour Mills of Nigeria Plc (FLOURMILL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Supervalu Inc (SVU):企業の財務・戦略的SWOT分析
    Supervalu Inc (SVU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Saracen Mineral Holdings Ltd:企業の戦略・SWOT・財務分析
    Saracen Mineral Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Saracen Mineral Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • J & J Snack Foods Corp:企業の戦略・SWOT・財務情報
    J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report Summary J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • India Glycols Ltd (INDIAGLYCO):企業の財務・戦略的SWOT分析
    India Glycols Ltd (INDIAGLYCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Shilpa Medicare Ltd (SHILPAMED):企業の財務・戦略的SWOT分析
    Shilpa Medicare Ltd (SHILPAMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Charles River Laboratories International Inc (CRL):企業の財務・戦略的SWOT分析
    Charles River Laboratories International Inc (CRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Tipco Asphalt Public Company Limited:企業の戦略・SWOT・財務情報
    Tipco Asphalt Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Tipco Asphalt Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • UniFirst Corp (UNF):企業の財務・戦略的SWOT分析
    UniFirst Corp (UNF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • JSFC Sistema (AFKS):石油・ガス:M&Aディール及び事業提携情報
    Summary JSFC Sistema (Sistema) is a diversified holding company which offers a wide range of consumer services in Russia and the Commonwealth of Independent States (CIS).The company undertakes businesses in various sectors, including telecommunications, high technology, real estate development, reta …
  • Tenaga Nasional Bhd (TENAGA):電力:M&Aディール及び事業提携情報
    Summary Tenaga Nasional Bhd (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also suppli …
  • OGE Energy Corp (OGE):企業の財務・戦略的SWOT分析
    OGE Energy Corp (OGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Xvivo Perfusion AB (XVIVO):企業の財務・戦略的SWOT分析
    Summary Xvivo Perfusion AB (Xvivo), a subsidiary of Bure Equity AB is a medical technology company that provides organ transplantation solutions. The company develops organ preservation products such as perfadex and silicone tubing sets and normothermic perfusion products. It offers normothermic per …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆